Biotech Stocks Morning Update – November 30, 2017


GTBP Sees Strong Bump & Now Breaking News!

GT Biopharma, Inc. (GTBP) saw a strong Wednesday session with a move from under $5 to highs of $6.50. This momentum comes on the heels of (GTBP)’s latest announcement that they will Present Data on Next Generation TriKE (OXS-C3550)! Dr. Jeffrey Miller, Deputy Director of the Masonic Cancer Center, University of Minnesota, will be presenting data on its second-generation anti-CD16-IL-15-anti-CD33 TriKE (OXS-C3550); another first of its kind, single-chain, tri-specific NK cell engager (TriKE). Being that OXS-3550 is expected to enter human clinical trials in 2018, this could be a critical time to be paying close attention to (GTBP)!

Click Here For Full Update

Biotech Investors are Hungry for the Next Big Buyout Target

The recent $12 billion acquisition of Kite Pharma, Inc. by big-pharma giant, Gilead Sciences has biotech investors hungry for the next big buyout target.

Click Here To See Full Article

BIOTECHSTOCKS,.com is owned by MIDAM VENTURES LLC., a Florida Corporation that has been compensated $1,050,000.00 by a GT Biopharma Inc. for a period beginning August 1, 2017 and ending Nov. 1, 2017 now extended to January 1, 2018 to publicly disseminate information about (GTBP). We own zero shares.


Please enter your name here
Please enter your comment!